A report released on April 30 recommends that the federal government monitor dialysis care to ensure that a new payment system for such care does not harm vulnerable populations (http://www.gao.gov/new.items/d10295.pdf).
To target increasing costs associated with dialysis care, especially for high-priced injectable erythropoiesis-stimulating agents, Congress required bundling of payments for end-stage renal disease (ESRD) treatment—paying a composite rate for routine services plus injectable drugs and certain laboratory tests—beginning in 2011.
Mitka M. Dialysis Bundling. JAMA. 2010;303(22):2241. doi:10.1001/jama.2010.719